Related Experiment Videos
Isolated limb perfusion: the European experience
F J Lejeune1, B B Kroon, F Di Filippo
1Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. ferdy.lejeune@chuv.hospvd.ch
Surgical Oncology Clinics of North America
|October 20, 2001
Summary
Isolated limb perfusion (ILP) delivers high-dose cancer drugs directly to a limb, achieving high remission rates for melanoma and sarcomas. This targeted approach enables limb-sparing surgery and demonstrates effective anti-angiogenic therapy.
Area of Science:
- Oncology
- Surgical Oncology
- Pharmacology
Background:
- Isolated limb perfusion (ILP) is a regional chemotherapy technique.
- It allows high-dose drug delivery while isolating the limb from systemic circulation.
- Melanoma and sarcomas are significant challenges in limb oncology.
Purpose of the Study:
- To evaluate the efficacy of ILP with melphalan for melanoma treatment.
- To assess ILP with tumor necrosis factor and melphalan as neoadjuvant therapy for sarcomas.
- To demonstrate the clinical application of an anti-angiogenic regimen.
Main Methods:
- ILP involves surgically isolating a limb and perfusing it with high-dose anticancer agents.
- Continuous leakage monitoring is employed during perfusion.
- Melanoma patients received melphalan via ILP.
- Sarcoma patients received ILP with tumor necrosis factor and melphalan.
Main Results:
- High complete remission rates were achieved in melanoma patients treated with melphalan ILP.
- ILP with tumor necrosis factor and melphalan proved effective as neoadjuvant treatment for limb-sparing surgery in sarcoma patients.
- The study demonstrated the first active anti-angiogenic regimen in clinical practice.
Conclusions:
- ILP with melphalan is effective for treating melanoma.
- ILP with tumor necrosis factor and melphalan is a viable neoadjuvant strategy for limb sarcomas.
- This approach represents a significant advancement in clinical anti-angiogenic therapy.